Cashing in on your genes
By Mark Henderson,
The Times
| 01. 07. 2010
Spitting is not an activity that has traditionally carried much social cachet. Yet at New York Fashion Week and the Davos World Economic Forum two years ago, an invitation to drool into a tube became one of the hottest tickets around. For Hollywood celebrities and business executives alike, the new place to see and be seen was at a "spit party".
At this 21st-century take on the Tupperware party guests would hand over a little saliva (and a few hundred dollars) to a Silicon Valley start-up called 23andMe. After the cocktails had slipped down the company would extract DNA from the VIP spittle to assess its new customers' chances of developing a hundred or so medical conditions and physical traits, from breast cancer to baldness.
The idea was one whose time seemed to have come. As science started to reveal how genetic influences shape our health, so a new breed of business was taking DNA out of the laboratory and turning it into a glamorous consumer product. Anne Wojcicki and Linda Avey, the telegenic founders of 23andMe, were soon extolling...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jonquilyn Hill, Vox | 10.18.2026
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...